Match!
Ilaria Maggio
University of Bologna
Retrospective cohort studyNeuroendocrine tumorsDiabetes mellitusGeneral surgeryMedicine
7Publications
2H-index
13Citations
What is this?
Publications 15
Newest
#1Filippo Gustavo Dall’Olio (UNIBO: University of Bologna)H-Index: 3
#2Ilaria Maggio (UNIBO: University of Bologna)H-Index: 2
Last. Andrea Ardizzoni (UNIBO: University of Bologna)H-Index: 48
view all 6 authors...
Abstract Objectives ICIs have been approved and are routinely administered regardless of performance status (PS), despite randomized clinical trials of ICIs alone or combined with chemotherapy or target therapy enrolled patients with ECOG PS 0 or 1, while patients with ECOG PS 2 or more were excluded. Materials and methods We carried out a meta-analysis of available clinical studies exploring the prognostic impact of PS > = 2 on Overall Survival (OS), Progression Free Survival (PFS) or Overall R...
Source
#1Giuseppe LambertiH-Index: 3
#2Lisa ManuzziH-Index: 2
Last. Davide CampanaH-Index: 25
view all 4 authors...
Source
#2Alessandro Rizzo (UNIBO: University of Bologna)
Last. Francesco MassariH-Index: 30
view all 6 authors...
Source
#1Giuseppe Lamberti (Harvard University)H-Index: 3
#2Sara PuscedduH-Index: 11
Last. Davide CampanaH-Index: 25
view all 7 authors...
Source
#1Ilaria MaggioH-Index: 2
#2Lisa ManuzziH-Index: 2
Last. Davide CampanaH-Index: 25
view all 6 authors...
Background: Neuroendocrine neoplasms are rare entities consisting of a heterogeneous group of tumors that can originate from neuroendocrine cells present in the whole body. Their different behavior, metastatic potential, and prognosis are highly variable, depending on site of origin, grade of differentiation, and proliferative index. The aim of our work is to summarize the current knowledge of immunotherapy in different neuroendocrine neoplasms and its implication in clinical practice. Results: ...
2 CitationsSource
#1Ilaria Maggio (UNIBO: University of Bologna)H-Index: 2
#2Veronica Mollica (UNIBO: University of Bologna)H-Index: 3
Last. Davide Campana (UNIBO: University of Bologna)H-Index: 25
view all 7 authors...
Purpose Insulinomas are a rare type of neuroendocrine tumors, originating in the pancreas, difficult to diagnose and to treat. Due to its rarity, insulinomas are a not well-known pathological entity; thus, the diagnostic process is frequently a medical challenge with many possible differential diagnoses. The diagnostic process varies between non-invasive procedures, such as the fasting test or imaging techniques, and invasive ones. Insulinomas are rarely malignant, but the glycemic imbalance cor...
Source
#1Alessandro Rizzo (UNIBO: University of Bologna)
#2Veronica Mollica (UNIBO: University of Bologna)H-Index: 3
Last. Andrea Ardizzoni (UNIBO: University of Bologna)H-Index: 48
view all 8 authors...
Aim: We performed a systematic review and meta-analysis to investigate the efficacy and safety of third-line (TLT) and salvage treatment (ST) in advanced or metastatic gastric cancer. Materials & methods: Eligible studies included randomized clinical trials assessing TLT and ST versus placebo or best supportive care. Outcomes of interest included: overall survival, objective response rate and disease control rate in TLT; progression-free survival in ST; grade 3-4 adverse events in ST. Results: T...
1 CitationsSource
Abstract Background Although prognosis of NENs is affected by several features including tumour burden, the specific role of this factor in pancreatic NENs (PanNENs) and gastrointestinal NENs (GI NENs) is not well established. Aim To compare the prognostic role of tumour burden in PanNENs and GI NENs. Patients and methods This study was a retrospective analysis of stage IV PanNENs and GI NENs. Tumours were classified based on liver tumour volume ( 25%). Overall survival as assessed by Kaplan-Mei...
Source
#1Nicole Brighi (UNIBO: University of Bologna)H-Index: 6
#2Giuseppe Lamberti (UNIBO: University of Bologna)H-Index: 3
Last. Davide Campana (UNIBO: University of Bologna)H-Index: 25
view all 12 authors...
Abstract Background Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs: an increased incidence has been reported in somatostatin analogs-treated acromegalic patients, but studies on patients with neuroendocrine neoplasms are lacking. Aims To evaluate biliary stone disease incidence and associated factors in a large series of patients treated with somatostatin analogs for neuroendocrine n...
2 CitationsSource
#1F. PanzutoH-Index: 4
#2Davide CampanaH-Index: 25
Last. Bruno AnnibaleH-Index: 48
view all 16 authors...
Source
12